Rifaximin Chemical

Product Description

We are offering high quality of Rifaximin. We are known for manufacturing, exporting, Distributing, trading and supplying Rifaximin in Gujarat, India. Further, this is safely Packaged by our professionals in diverse packaging options that maintain its purity and Effectiveness.

Shreeji Pharma International is leading Manufacturer, Exporter, Distributor, and Supplier of Rifaximin in Gujarat. India. Shreeji Pharma International manufacturing & supplying all Products under GMP site with all types of regulatory supports.

Shreeji Pharma International is the largest manufacturer, Exporter and supplier of Rifaximin Nowadays Shreeji Pharma International is one of the leading manufacturer And exporter, who is manufacturing Cevimeline HCL as well as Intermediates of Cevimeline HCL.

Shreeji Pharma International is exporter, supplier, distributor and manufacturers of the Active Pharmaceuticals Ingredients in many countries for many years. Shreeji Pharma International currently export Cevimeline HCL to countries like Gulf Countries, South East Asia countries, African Countries, CIS Countries, LATAM countries, Central American Countries and in European countries

Rifaximin is a non-systemic broad-spectrum antibiotic, structurally related to rifamycin. It is mainly used for treating gastrointestinal infections. The powder form is typically used as a raw material in pharmaceutical formulations such as tablets or suspensions.

• Molecular Formula: C43H51NO11
• Molecular Weight: 785.88 g/mol
• Appearance: Light red to reddish-orange crystalline powder
• Solubility: Practically insoluble in water; slightly soluble in methanol and ethanol
• Storage Conditions: Store in a tightly closed container at 2C to 8C; protect from light and moisture
• Indications (for powder form use, based on compounding or oral reconstitution):
• Travelers Diarrhea caused by non-invasive strains of Escherichia coli
• Hepatic Encephalopathy (to reduce the risk of overt episodes)
• Irritable Bowel Syndrome with Diarrhea (IBS-D)
• Small Intestinal Bacterial Overgrowth (SIBO) (off-label)
• Difficile infection (off-label and investigational uses)
• Common side effects: Nausea, flatulence, headache, abdominal pain
• Rare: Allergic reactions, C. difficile-associated diarrhea Not suitable for systemic infections due to minimal absorption

Precautions:

• Hypersensitivity: Avoid in patients with known hypersensitivity to rifaximin, rifampin, or other rifamycin derivatives.
• Severe Hepatic Impairment (Child-Pugh C): Use caution due to increased systemic exposure.
• Antibiotic Resistance: Misuse can lead to drug-resistant bacteria. Use only as prescribed.

Difficile-associated Diarrhea (CDAD): Watch for signs; discontinue if suspected.

Pregnancy and Breastfeeding:

• Pregnancy Category: B (animal studies show no risk, human data limited)
• Lactation: Unknown if excreted in human milk; caution advised.
• Pediatric Use: Safety and efficacy vary by age and indication. Not recommended for children under 12 for some uses.
• Warnings:Do not inhale powder. May cause respiratory irritation.
• Not for intravenous or injectable use.
• For oral use only (when properly compounded or reconstituted).
• Store securely and away from children.
• Discontinue use if severe allergic reaction occurs (e.g., rash, swelling, difficulty breathing).
• Avoid unnecessary or prolonged use to reduce the risk of bacterial resistance.